ciprofloxacin has been researched along with Infections, Yersinia in 21 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciprofloxacin was not effective in Yersinia- or Salmonella-induced arthritis but seemed to be better than placebo in Chlamydia-induced arthritis." | 2.69 | No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. ( Alten, R; Braun, J; Eggens, U; Fendler, C; Granfors, K; Gripenberg-Lerche, C; Groh, A; Hiepe, F; Keitel, W; Laitko, S; Sieper, J; Sörensen, H; Uksila, J, 1999) |
| "Patients with yersinia triggered reactive arthritis were double blind randomly allocated to receive treatment with ciprofloxacin 500 mg twice daily orally or placebo during three months." | 2.69 | Ciprofloxacin v placebo for treatment of Yersinia enterocolitica triggered reactive arthritis. ( Bruyn, GA; Hoogkamp-Korstanje, JA; Moesker, H, 2000) |
| "Oral ciprofloxacin was used as the principal antimicrobial agent in the patients described here and therapeutic success was achieved in three of these patients." | 2.39 | Clinical features and antibiotic treatment of septic arthritis and osteomyelitis due to Yersinia enterocolitica. ( Ashford, K; Crowe, M; Ispahani, P, 1996) |
| "After diagnostic work-up, we diagnosed Yersinia enterocolitica infection." | 1.31 | Case report: an unusual presentation of Yersinia enterocolitica infection. ( Begashaw, K; Jaspers, CA, 2001) |
| "We conclude that experimental Yersinia reactive arthritis can be cured by antibiotics introduced at an early phase of arthritic development." | 1.30 | Experimental Yersinia-triggered reactive arthritis: effect of a 3-week course of ciprofloxacin. ( Toivanen, A; Toivanen, P; Zhang, Y, 1997) |
| "Amikacin was less effective." | 1.30 | Comparison of ceftriaxone, amikacin, and ciprofloxacin in treatment of experimental Yersinia enterocolitica O9 infection in mice. ( Gonzalez-Torres, C; Jiménez-Valera, M; Moreno, E; Ruiz-Bravo, A, 1998) |
| " If a dosage of 20 mg/kg/day was used, development of acute arthritis was prevented, but some of the animals had positive fecal cultures at the end of experiment." | 1.29 | Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model. ( Gripenberg-Lerche, C; Söderström, KO; Toivanen, A; Toivanen, P; Zhang, Y, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (38.10) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lübbert, C | 1 |
| Fàbrega, A | 1 |
| Vila, J | 2 |
| Sieper, J | 2 |
| Braun, J | 2 |
| Capilla, S | 1 |
| Ruiz, J | 1 |
| Goñi, P | 1 |
| Castillo, J | 1 |
| Rubio, MC | 1 |
| Jiménez de Anta, MT | 1 |
| Gómez-Lus, R | 1 |
| Abad, C | 1 |
| Ponce, G | 1 |
| Elcuaz, R | 1 |
| Grigull, L | 1 |
| Linderkamp, C | 1 |
| Sander, A | 1 |
| Schmid, H | 1 |
| Mutschler, U | 1 |
| Welte, K | 1 |
| Beilken, A | 1 |
| Navarro-Llavat, M | 1 |
| Domènech, E | 1 |
| Masnou, H | 1 |
| Ojanguren, I | 1 |
| Mañosa, M | 1 |
| Lorenzo-Zúñiga, V | 1 |
| Boix, J | 1 |
| Gassull, MA | 1 |
| Kelesidis, T | 1 |
| Balba, G | 1 |
| Worthington, M | 1 |
| Zhang, Y | 2 |
| Gripenberg-Lerche, C | 2 |
| Söderström, KO | 1 |
| Toivanen, A | 4 |
| Toivanen, P | 3 |
| Crowe, M | 1 |
| Ashford, K | 1 |
| Ispahani, P | 1 |
| Wintersperger, BJ | 1 |
| Seemann, M | 1 |
| Sauter, G | 1 |
| Fink, U | 1 |
| Reiser, M | 1 |
| Jiménez-Valera, M | 1 |
| Gonzalez-Torres, C | 1 |
| Moreno, E | 1 |
| Ruiz-Bravo, A | 1 |
| Fendler, C | 1 |
| Laitko, S | 1 |
| Sörensen, H | 1 |
| Hiepe, F | 1 |
| Alten, R | 1 |
| Keitel, W | 1 |
| Groh, A | 1 |
| Uksila, J | 1 |
| Eggens, U | 1 |
| Granfors, K | 1 |
| Hoogkamp-Korstanje, JA | 1 |
| Moesker, H | 1 |
| Bruyn, GA | 1 |
| Jaspers, CA | 1 |
| Begashaw, K | 1 |
| Roussos, A | 1 |
| Stambori, M | 1 |
| Aggelis, P | 1 |
| Kanavaki, S | 1 |
| Garzonis, P | 1 |
| Makarona, M | 1 |
| Kapralos, C | 1 |
| Karambela, S | 1 |
| Dalamaga, A | 1 |
| Ferti, A | 1 |
| Zöllner, B | 1 |
| Sobottka, I | 1 |
| von der Lippe, G | 1 |
| Boyens, M | 1 |
| Pokahr, A | 1 |
| Grüter, L | 1 |
| Laufs, R | 1 |
| Read, RC | 1 |
| Barry, RE | 1 |
6 reviews available for ciprofloxacin and Infections, Yersinia
| Article | Year |
|---|---|
Antimicrobial therapy of acute diarrhoea: a clinical review.
Topics: Acute Disease; Aminoglycosides; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Campyloba | 2016 |
[Diagnosis and antibiotic treatment of reactive arthritis].
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Arthritis, Reactive; A | 2002 |
Collagenous duodeno-ileo-colitis with transient IgG deficiency preceded by Yersinia enterocolitica intestinal infection: case report and review of literature.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Budesonide; Chronic Disease; Ciprofloxacin; Colitis | 2007 |
Clinical features and antibiotic treatment of septic arthritis and osteomyelitis due to Yersinia enterocolitica.
Topics: Administration, Oral; Adolescent; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Age | 1996 |
Managing reactive arthritis.
Topics: Animals; Arthritis, Reactive; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Humans; Y | 2000 |
Reactive arthritis.
Topics: Animals; Arthritis, Reactive; Chlamydia Infections; Chlamydia trachomatis; Ciprofloxacin; DNA, Bacte | 2000 |
2 trials available for ciprofloxacin and Infections, Yersinia
| Article | Year |
|---|---|
No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study.
Topics: Adult; Aged; Anti-Infective Agents; Arthritis, Reactive; Chlamydia Infections; Chlamydia trachomatis | 1999 |
Ciprofloxacin v placebo for treatment of Yersinia enterocolitica triggered reactive arthritis.
Topics: Adolescent; Adult; Aged; Animals; Anti-Infective Agents; Arthritis, Reactive; Blood Sedimentation; C | 2000 |
13 other studies available for ciprofloxacin and Infections, Yersinia
| Article | Year |
|---|---|
Heterogeneity in the selection of quinolone target gene mutations upon exposure to ciprofloxacin in Yersinia enterocolitica.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Drug Resistance, | 2011 |
Characterization of the molecular mechanisms of quinolone resistance in Yersinia enterocolitica O:3 clinical isolates.
Topics: Anti-Infective Agents; Ciprofloxacin; Dipeptides; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, | 2004 |
Early vascular graft infection due to Yersinia enterocolitica after repair of an abdominal aortic aneurysm.
Topics: Aged; Anti-Bacterial Agents; Aortic Aneurysm, Abdominal; Blood Vessel Prosthesis; Blood Vessel Prost | 2004 |
Multiple spleen and liver abscesses due to Yersinia enterocolitica septicemia in a child with congenital sideroblastic anemia.
Topics: Anemia, Sideroblastic; Anti-Bacterial Agents; Bacteremia; Child, Preschool; Ciprofloxacin; Humans; I | 2005 |
Axillary abscess in a patient with Yersinia enterocolitica infection as a result of exposure to pork.
Topics: Abscess; Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Ciprofloxaci | 2008 |
Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Arthritis, Reactive; Body Weight; Ciprofloxa | 1996 |
[Disseminated liver abscesses in yersiniosis: diagnosis by ultrasound and spiral CT].
Topics: Anti-Infective Agents; Cefotaxime; Cephalosporins; Ciprofloxacin; Female; Humans; Liver Abscess; Mid | 1996 |
Experimental Yersinia-triggered reactive arthritis: effect of a 3-week course of ciprofloxacin.
Topics: Animals; Anti-Infective Agents; Antibodies, Bacterial; Arthritis, Reactive; Ciprofloxacin; Dose-Resp | 1997 |
Comparison of ceftriaxone, amikacin, and ciprofloxacin in treatment of experimental Yersinia enterocolitica O9 infection in mice.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Feces; Female; Intestinal Dise | 1998 |
Case report: an unusual presentation of Yersinia enterocolitica infection.
Topics: Acute Disease; Adult; Anti-Infective Agents; Biopsy; Ciprofloxacin; Colonoscopy; Diagnosis, Differen | 2001 |
Transfusion-mediated Yersinia enterocolitica septicemia in an adult patient with beta-thalassemia.
Topics: Adult; Anti-Infective Agents; beta-Thalassemia; Ceftriaxone; Cephalosporins; Ciprofloxacin; Female; | 2001 |
[Perimyocarditis caused by Yersinia enterocolitica serotype 0:3].
Topics: Adult; Antibodies, Bacterial; Chest Pain; Ciprofloxacin; Electrocardiography; Feces; Humans; Immunob | 1992 |
Relapsing yersinia infection.
Topics: Adult; Chronic Disease; Ciprofloxacin; Female; Humans; Recurrence; Yersinia enterocolitica; Yersinia | 1990 |